We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+42.04%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$2.01B
AUM Growth
+$128M
Cap. Flow
-$241M
Cap. Flow %
-12%
Top 10 Hldgs %
57.08%
Holding
77
New
4
Increased
7
Reduced
4
Closed
25

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$34.9M
2
GPCR icon
Structure Therapeutics
GPCR
+$22.9M
3
ARVN icon
Arvinas
ARVN
+$14.2M
4
TNGX icon
Tango Therapeutics
TNGX
+$9.33M
5
IMVT icon
Immunovant
IMVT
+$9.2M

Top Sells

Rank Stock Value
1
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$38.2M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$36.5M
3
VTYX
Ventyx Biosciences
VTYX
+$29.5M
4
FOLD
Amicus Therapeutics
FOLD
+$28.3M
5
EXEL icon
Exelixis
EXEL
+$25.1M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PNT
76
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
– –
-2,500,000
Closed -$16.7M
EQRX
77
DELISTED
EQRx, Inc. Common Stock
EQRX
– –
-1,000,000
Closed -$2.22M
1 2 3
4

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q4 2023 Portfolio in Review

As of Q4 2023, Boxer Capital held 77 positions worth $2.01B, up 6.8% from $1.88B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Boxer Capital withdrew a net $241M in Q4 2023, closing 25 positions and reducing 4 holdings. Its most notable exit was Amylyx Pharmaceuticals, an estimated $38.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier.

Against the trend, Boxer Capital opened a new position in Structure Therapeutics worth $16.3M.

  • Boxer Capital's largest Q4 2023 buy was Structure Therapeutics: 400,000 shares worth $16.3M.
  • Boxer Capital added most to argenx in Q4 2023, an estimated $34.9M increase.
  • Boxer Capital's biggest Q4 2023 reduction was Iovance Biotherapeutics, cutting an estimated $12.1M.
  • Boxer Capital fully exited Amylyx Pharmaceuticals in Q4 2023, selling an estimated $38.2M.
  • Boxer Capital's ten largest holdings make up 57% of its $2.01B portfolio in Q4 2023.
  • Boxer Capital opened 4 new positions and closed 25 in Q4 2023.
  • Boxer Capital's portfolio value rose 6.8% quarter-over-quarter to $2.01B.

Based on Boxer Capital's 13F filing for Q4 2023, filed 14 Feb 2024.